merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Safety concerns and lack of FDA oversight</answer>
<question_number>2</question_number>
<answer>LillyDirect allows patients to purchase Zepbound vials directly, bypassing telehealth companies</answer>
<question_number>3</question_number>
<answer>Lack of FDA oversight and potential for quality and safety issues</answer>
<question_number>4</question_number>
<answer>It could attract patients who cannot afford the pens, regaining market share lost to cheaper alternatives</answer>
<question_number>5</question_number>
<answer>Lilly argues that when tirzepatide is removed from the shortage list, there is no justification for compounding pharmacies to continue producing it</answer>
<question_number>6</question_number>
<answer>Selling directly to consumers allows for "transparent pricing" by removing intermediaries</answer>
<question_number>7</question_number>
<answer>Older patients on Medicare may be more susceptible to the risks of weight-loss drugs, and the lack of coverage could lead them to seek cheaper, potentially unsafe alternatives</answer>
<question_number>8</question_number>
<answer>It could make patients perceive Lilly's vials as a safer option</answer>
<question_number>9</question_number>
<answer>Tirzepatide is listed as "in shortage" by the FDA</answer>
<question_number>10</question_number>
<answer>Lowering prices to undercut the market</answer>